Clinical significance of serum anti-human papillomavirus 16 and 18 antibodies in cervical neoplasia

Doo Byung Chay, Hanbyoul Cho, Bo Wook Kim, Eun Suk Kang, Eunseop Song, Jae-Hoon Kim

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: To estimate the clinical significance of serum anti-human papillomavirus (HPV) antibodies and high-risk cervical HPV DNA in cervical neoplasia. Methods: The study population comprised patients who were histopathologically diagnosed with cervical intraepithelial neoplasia (CIN) 1 (n=64), CIN 2 and 3 (n=241), cervical cancer (n=170), and normal control participants (n=975). Cervical HPV DNA tests were performed through nucleic acid hybridization assay tests, and serum anti-HPV 16 and 18 antibodies were measured by competitive immunoassay. The associations of HPV DNA and anti-HPV antibodies were evaluated with demographic characteristics and compared according to the levels of disease severity. Anti-HPV antibodies were also investigated with clinicopathologic parameters, including survival data. Results: Among various demographic characteristics, factors involving sexual behavior had a higher tendency of HPV DNA positivity and HPV seropositivity. Human papillomavirus DNA mean titer and positivity were both increased in patients with cervical neoplasia compared with those with normal control participants, but there was no statistical difference among types of cervical neoplasia. Serum anti-HPV 16 antibodies were also able to differentiate cervical neoplasia from a normal control participant and furthermore distinguished CIN 1 from CIN 2 and 3 (odd ratio 2.87 [1.43-5.78], P=.002). In cervical cancer, HPV 16 seropositivity was associated with prolonged disease-free survival according to the univariable analysis (hazard ratio=0.12 [0.01-0.94], P=.044). Conclusion: Serum anti-HPV 16 antibodies can distinguish cervical neoplasia from a normal control and has the advantage of identifying high-grade CIN. Moreover, in cervical cancer, HPV 16 seropositivity may be associated with a more favorable prognosis.

Original languageEnglish
Pages (from-to)321-329
Number of pages9
JournalObstetrics and Gynecology
Volume121
Issue number2 PART 1
DOIs
Publication statusPublished - 2013 Feb 1

Fingerprint

Human papillomavirus 18
Human papillomavirus 16
Cervical Intraepithelial Neoplasia
Antibodies
Serum
Neoplasms
Uterine Cervical Neoplasms
DNA
Human Papillomavirus DNA Tests
Demography
Nucleic Acid Hybridization
Immunoassay
Sexual Behavior
Disease-Free Survival
Odds Ratio
Survival

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynaecology

Cite this

Chay, Doo Byung ; Cho, Hanbyoul ; Kim, Bo Wook ; Kang, Eun Suk ; Song, Eunseop ; Kim, Jae-Hoon. / Clinical significance of serum anti-human papillomavirus 16 and 18 antibodies in cervical neoplasia. In: Obstetrics and Gynecology. 2013 ; Vol. 121, No. 2 PART 1. pp. 321-329.
@article{a9a19a7d19fb443a912a1bb69c20c052,
title = "Clinical significance of serum anti-human papillomavirus 16 and 18 antibodies in cervical neoplasia",
abstract = "Objective: To estimate the clinical significance of serum anti-human papillomavirus (HPV) antibodies and high-risk cervical HPV DNA in cervical neoplasia. Methods: The study population comprised patients who were histopathologically diagnosed with cervical intraepithelial neoplasia (CIN) 1 (n=64), CIN 2 and 3 (n=241), cervical cancer (n=170), and normal control participants (n=975). Cervical HPV DNA tests were performed through nucleic acid hybridization assay tests, and serum anti-HPV 16 and 18 antibodies were measured by competitive immunoassay. The associations of HPV DNA and anti-HPV antibodies were evaluated with demographic characteristics and compared according to the levels of disease severity. Anti-HPV antibodies were also investigated with clinicopathologic parameters, including survival data. Results: Among various demographic characteristics, factors involving sexual behavior had a higher tendency of HPV DNA positivity and HPV seropositivity. Human papillomavirus DNA mean titer and positivity were both increased in patients with cervical neoplasia compared with those with normal control participants, but there was no statistical difference among types of cervical neoplasia. Serum anti-HPV 16 antibodies were also able to differentiate cervical neoplasia from a normal control participant and furthermore distinguished CIN 1 from CIN 2 and 3 (odd ratio 2.87 [1.43-5.78], P=.002). In cervical cancer, HPV 16 seropositivity was associated with prolonged disease-free survival according to the univariable analysis (hazard ratio=0.12 [0.01-0.94], P=.044). Conclusion: Serum anti-HPV 16 antibodies can distinguish cervical neoplasia from a normal control and has the advantage of identifying high-grade CIN. Moreover, in cervical cancer, HPV 16 seropositivity may be associated with a more favorable prognosis.",
author = "Chay, {Doo Byung} and Hanbyoul Cho and Kim, {Bo Wook} and Kang, {Eun Suk} and Eunseop Song and Jae-Hoon Kim",
year = "2013",
month = "2",
day = "1",
doi = "10.1097/AOG.0b013e31827c59f7",
language = "English",
volume = "121",
pages = "321--329",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "2 PART 1",

}

Clinical significance of serum anti-human papillomavirus 16 and 18 antibodies in cervical neoplasia. / Chay, Doo Byung; Cho, Hanbyoul; Kim, Bo Wook; Kang, Eun Suk; Song, Eunseop; Kim, Jae-Hoon.

In: Obstetrics and Gynecology, Vol. 121, No. 2 PART 1, 01.02.2013, p. 321-329.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical significance of serum anti-human papillomavirus 16 and 18 antibodies in cervical neoplasia

AU - Chay, Doo Byung

AU - Cho, Hanbyoul

AU - Kim, Bo Wook

AU - Kang, Eun Suk

AU - Song, Eunseop

AU - Kim, Jae-Hoon

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Objective: To estimate the clinical significance of serum anti-human papillomavirus (HPV) antibodies and high-risk cervical HPV DNA in cervical neoplasia. Methods: The study population comprised patients who were histopathologically diagnosed with cervical intraepithelial neoplasia (CIN) 1 (n=64), CIN 2 and 3 (n=241), cervical cancer (n=170), and normal control participants (n=975). Cervical HPV DNA tests were performed through nucleic acid hybridization assay tests, and serum anti-HPV 16 and 18 antibodies were measured by competitive immunoassay. The associations of HPV DNA and anti-HPV antibodies were evaluated with demographic characteristics and compared according to the levels of disease severity. Anti-HPV antibodies were also investigated with clinicopathologic parameters, including survival data. Results: Among various demographic characteristics, factors involving sexual behavior had a higher tendency of HPV DNA positivity and HPV seropositivity. Human papillomavirus DNA mean titer and positivity were both increased in patients with cervical neoplasia compared with those with normal control participants, but there was no statistical difference among types of cervical neoplasia. Serum anti-HPV 16 antibodies were also able to differentiate cervical neoplasia from a normal control participant and furthermore distinguished CIN 1 from CIN 2 and 3 (odd ratio 2.87 [1.43-5.78], P=.002). In cervical cancer, HPV 16 seropositivity was associated with prolonged disease-free survival according to the univariable analysis (hazard ratio=0.12 [0.01-0.94], P=.044). Conclusion: Serum anti-HPV 16 antibodies can distinguish cervical neoplasia from a normal control and has the advantage of identifying high-grade CIN. Moreover, in cervical cancer, HPV 16 seropositivity may be associated with a more favorable prognosis.

AB - Objective: To estimate the clinical significance of serum anti-human papillomavirus (HPV) antibodies and high-risk cervical HPV DNA in cervical neoplasia. Methods: The study population comprised patients who were histopathologically diagnosed with cervical intraepithelial neoplasia (CIN) 1 (n=64), CIN 2 and 3 (n=241), cervical cancer (n=170), and normal control participants (n=975). Cervical HPV DNA tests were performed through nucleic acid hybridization assay tests, and serum anti-HPV 16 and 18 antibodies were measured by competitive immunoassay. The associations of HPV DNA and anti-HPV antibodies were evaluated with demographic characteristics and compared according to the levels of disease severity. Anti-HPV antibodies were also investigated with clinicopathologic parameters, including survival data. Results: Among various demographic characteristics, factors involving sexual behavior had a higher tendency of HPV DNA positivity and HPV seropositivity. Human papillomavirus DNA mean titer and positivity were both increased in patients with cervical neoplasia compared with those with normal control participants, but there was no statistical difference among types of cervical neoplasia. Serum anti-HPV 16 antibodies were also able to differentiate cervical neoplasia from a normal control participant and furthermore distinguished CIN 1 from CIN 2 and 3 (odd ratio 2.87 [1.43-5.78], P=.002). In cervical cancer, HPV 16 seropositivity was associated with prolonged disease-free survival according to the univariable analysis (hazard ratio=0.12 [0.01-0.94], P=.044). Conclusion: Serum anti-HPV 16 antibodies can distinguish cervical neoplasia from a normal control and has the advantage of identifying high-grade CIN. Moreover, in cervical cancer, HPV 16 seropositivity may be associated with a more favorable prognosis.

UR - http://www.scopus.com/inward/record.url?scp=84873868118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873868118&partnerID=8YFLogxK

U2 - 10.1097/AOG.0b013e31827c59f7

DO - 10.1097/AOG.0b013e31827c59f7

M3 - Article

VL - 121

SP - 321

EP - 329

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 2 PART 1

ER -